Navigation Links
BiPar Names Hoyoung Huh, M.D., Ph.D. President and Chief Executive Officer
Date:2/14/2008

BRISBANE, Calif., Feb. 14 /PRNewswire/ -- BiPar Sciences, Inc., a privately held biopharmaceutical company developing novel cancer therapeutics, announced that Hoyoung Huh, M.D., Ph.D., has been appointed President and Chief Executive Officer and will commence his new role on March 3, 2008.

Dr. Huh previously served as Chief Operating Officer and Head of the Pegylation Business Unit at Nektar Therapeutics, a drug development company in the therapeutic areas of oncology, CNS/pain, diabetes and infectious diseases. At Nektar, Dr. Huh led significant, revenue-generating partnerships with major pharmaceutical companies including Amgen Inc., Bayer AG, Baxter International Inc., Bristol-Myers Squibb Co., Novartis AG and Roche Holding Ltd. Dr. Huh managed more than 500 employees across global sites in key functions including research, clinical development, manufacturing, marketing and business development. He was also instrumental in establishing multiple new product partnerships and led the acquisition and divestiture of several entities.

Prior to Nektar, Dr. Huh was a partner with McKinsey & Company, serving biotechnology, biopharmaceutical and healthcare clients in the United States, Europe and Asia. He has been an industry thought leader and frequent speaker on topics including licensing, mergers and acquisitions and innovative product development and commercialization strategies. Dr. Huh serves on the board of directors of BayBio, a biotechnology industry association, and Nektar Therapeutics.

"Hoyoung is ideally suited to lead BiPar through this period of expansion and change, with a robust Phase 2 program underway with BSI-201, a potential best-in-class cancer therapy," said G. Kirk Raab, chairman of BiPar, who had served as acting CEO prior to Dr. Huh's appointment. "His business development experience is exceptional, and there is no doubt that Hoyoung will maximize the value of BiPar's programs through rigorous clinical development and well-considered partnerships."

BiPar is developing multiple compounds designed to inhibit PARP-1 (poly-ADP-ribose polymerase), an enzyme crucial to DNA repair that is upregulated in certain tumors. The company's lead compound, BSI-201, has entered a series of Phase 2 trials in tumors types where PARP is overexpressed. The first of those trials will evaluate BSI-201 in patients with "triple negative" breast cancer, and BiPar expects to begin trials in brain and uterine cancers later this quarter.

"BiPar has an extraordinary platform of product candidates, a robust biomarker-driven clinical development plan for its lead program, BSI-201, and an industry-leading management team and board of directors," said Dr. Huh. "I look forward to building BiPar into a leading oncology company by leveraging its exciting product platform in DNA repair."

Dr. Huh received his M.D. and Ph.D. from Cornell University Medical College/Memorial Sloan Kettering Cancer Center and his A.B. from Dartmouth College.

About BiPar Sciences

BiPar Sciences, Inc. (http://www.biparsciences.com) is a clinical-stage biopharmaceutical company developing and commercializing a novel class of tumor-selective drugs designed to meet the significant unmet needs of cancer patients.


'/>"/>
SOURCE BiPar Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. WellGen, Inc. Names Robert M. Hellauer as Chief Financial Officer
2. Xenome Names Ian T. Nisbet, PhD as Chief Executive Officer
3. Profectus BioSciences Inc. Names Shawn Patrick OBrien CEO
4. VIA Pharmaceuticals Names Rebecca Taub Senior Vice President of Research and Development
5. CNS Response, Inc Completes Neuro-Therapy Clinic Acquisition; Names Daniel A. Hoffman, MD Chief Medical Officer
6. Premier Research Names Patrick Melvin as Senior Director, Clinical Trial Management
7. DuPont Names Nicholas Fanandakis as Group Vice President - DuPont Applied BioSciences
8. PAREXEL Names Biopharmaceutical Industry Executive Eduard E. Holdener to Board of Directors
9. Quintiles Names Kelly McKee Executive Director of Operations for Public Health and Government Services Unit
10. SRA Names Timothy J. Atkin Senior Vice President of Global Health Business; Appoints Mike Toner Global Health Unit Chief Financial Officer
11. Romark Laboratories Names Emmet B. Keeffe, M.D. Vice President and Chief Medical Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... KBioBox llc ... to client demand KbioBox developed a sophisticated “3 click” gene dditing off target ... from KBioBox’s new website, https://www.kbiobox.com/ and powered by the company’s ...
(Date:12/8/2016)... CA (PRWEB) , ... December 08, 2016 , ... ... as finalists in the World Technology Awards. uBiome is one of just six ... across all categories. , In addition to uBiome, companies nominated as finalists in ...
(Date:12/8/2016)... PRINCETON, N.J. , Dec. 8, 2016 /PRNewswire/ ... a late-stage biopharmaceutical company focused on developing and ... is an unmet medical need, announced today the ... trial with SGX942 (dusquetide), a first-in-class Innate Defense ... (OM) in head and neck cancer patients undergoing ...
(Date:12/8/2016)... TAMPA, Fla. , Dec. 8, 2016 /PRNewswire/ ... biopharmaceutical company that discovers, develops and plans to ... today that its shares of common stock were approved ... stock will begin trading on the OTCQX, effective ... To qualify for the OTCQX market, companies must ...
Breaking Biology Technology:
(Date:11/16/2016)... Sensory Inc ., a Silicon ... consumer electronics, and VeriTran , a technology ... today announced a global partnership that will provide ... users of mobile banking and mobile payments solutions.  ... which requires no specialized biometric scanners, yet provides ...
(Date:6/27/2016)... -- Research and Markets has announced the addition of ... their offering. The report forecasts ... grow at a CAGR of 12.28% during the period 2016-2020. ... market analysis with inputs from industry experts. The report covers the ... report also includes a discussion of the key vendors operating in ...
(Date:6/20/2016)... 20, 2016 Securus Technologies, a leading ... for public safety, investigation, corrections and monitoring announced ... it has secured the final acceptance by all ... Managed Access Systems (MAS) installed. Furthermore, Securus will ... be installed by October, 2016. MAS distinguishes between ...
Breaking Biology News(10 mins):